my personal edition > allergy other > news
E-Mail this DGReview to a colleague
DGReview
Budesonide Better For Quality of Life In Allergic Rhinitis
A DGReview of :"Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis"
Allergy
07/05/2002
By Elda Hauschildt
Both fluticasone and budesonide therapies are effective in treating seasonal allergic rhinitis but when compared, budesonide results in greater improvements in quality of life, European researchers report.
Investigators from two Italian and three French centres randomised 280 patients to once daily budesonide, fluticasone or placebo for five weeks.
Changes in combined nasal symptoms were used as the primary efficacy variable. Symptoms included nasal blockage, running nose and sneezing.
The researchers measured quality of life changes in 121 patients through two instruments: the rhinoconjunctivitis quality of life questionnaire and the short-form health (SF-36) survey.
Both steroid therapies significantly reduced combined nasal symptoms in the patients and there was no significant difference between the two therapies.
Substantial or total symptom control occurred in 89.9 percent of the budesonide patients and in 88.7 percent of the fluticasone patients.
With budesonide, patients showed improvements on four of five of the rhinoconjunctivitis questionnaire domains and in five of eight of the SF-36 domains.
With fluticasone, improvements were seen in only two rhinoconjunctivitis questionnaire domains and none of the SF-36 domains.
Allergy, 2002; 57: 586-591
"Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis"
All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.
| 
